U.S. Markets closed

Karuna Therapeutics, Inc. (KRTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
135.95+6.71 (+5.19%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close129.24
Open129.06
Bid94.42 x 900
Ask175.00 x 3000
Day's Range126.36 - 137.09
52 Week Range69.58 - 146.97
Volume231,093
Avg. Volume152,187
Market Cap4.005B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.90
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est159.62
  • Karuna Therapeutics to Present at Upcoming Investor Conferences
    Business Wire

    Karuna Therapeutics to Present at Upcoming Investor Conferences

    Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will present at the following upcoming virtual investor conferences:

  • Is It Too Late to Buy Karuna Therapeutics (KRTX) Stock?
    Insider Monkey

    Is It Too Late to Buy Karuna Therapeutics (KRTX) Stock?

    Miller Value Partners recently released its Q1 2021 Investor Letter, a copy of which you can download here. The Miller Opportunity Trust posted solid gains, with Class I up 16.67%, outperforming its benchmark, the S&P 500 Index which returned 6.17% in the same quarter. You should check out Miller Value Partners’ top 5 stock picks […]

  • Karuna Therapeutics Reports First Quarter 2021 Financial Results and Provides General Business Update
    Business Wire

    Karuna Therapeutics Reports First Quarter 2021 Financial Results and Provides General Business Update

    Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the first quarter of 2021 and provided a general business update.